- Home
- LEGT vs CAPR Comparison
LEGT vs CAPR Comparison
Compare LEGT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- CAPR
- Stock Information
- Founded
- LEGT 2023
- CAPR 2005
- Country
- LEGT United States
- CAPR United States
- Employees
- LEGT N/A
- CAPR N/A
- Industry
- LEGT
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGT
- CAPR Health Care
- Exchange
- LEGT Nasdaq
- CAPR Nasdaq
- Market Cap
- LEGT 278.6M
- CAPR 324.6M
- IPO Year
- LEGT 2024
- CAPR N/A
- Fundamental
- Price
- LEGT $10.89
- CAPR $6.27
- Analyst Decision
- LEGT
- CAPR Strong Buy
- Analyst Count
- LEGT 0
- CAPR 6
- Target Price
- LEGT N/A
- CAPR $23.00
- AVG Volume (30 Days)
- LEGT 5.7K
- CAPR 1.2M
- Earning Date
- LEGT 01-01-0001
- CAPR 11-10-2025
- Dividend Yield
- LEGT N/A
- CAPR N/A
- EPS Growth
- LEGT N/A
- CAPR N/A
- EPS
- LEGT 0.33
- CAPR N/A
- Revenue
- LEGT N/A
- CAPR $13,392,150.00
- Revenue This Year
- LEGT N/A
- CAPR N/A
- Revenue Next Year
- LEGT N/A
- CAPR $7,894.07
- P/E Ratio
- LEGT $33.12
- CAPR N/A
- Revenue Growth
- LEGT N/A
- CAPR N/A
- 52 Week Low
- LEGT $10.25
- CAPR $5.68
- 52 Week High
- LEGT $10.95
- CAPR $20.75
- Technical
- Relative Strength Index (RSI)
- LEGT 58.75
- CAPR 46.12
- Support Level
- LEGT $10.61
- CAPR $6.00
- Resistance Level
- LEGT $10.90
- CAPR $7.08
- Average True Range (ATR)
- LEGT 0.08
- CAPR 0.35
- MACD
- LEGT 0.00
- CAPR -0.00
- Stochastic Oscillator
- LEGT 96.97
- CAPR 24.69
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.